News

4 More Canadian Provinces Add Erelzi to Public Drug Plans for Inflammatory Diseases

The Canadian provinces of Manitoba, Saskatchewan, Alberta, and Newfoundland have joined others in adding Sandoz’s biosimilar Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases including ankylosing spondylitis. A biosimilar of the reference medicine Enbrel, Erelzi is a tumor necrosis factor (TNF)-alpha inhibitor, which means…

NIH Agency Pioneers Collaborative Research into Rare Diseases

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…